Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Jason Efstathiou, MD, Dphil
Open to Accrual
Activation Date: April 19, 2019
To compare bladder intact event-free survival (BI-EFS) for concurrent chemoradiation therapy (CRT) with and without atezolizumab in localized muscle invasive bladder cancer (MIBC).
This is a Joint SWOG & NRG Oncology FDA registration-intent trial. NRG Oncology institutions can credit NRG for their case accrual. NRG Canadian member sites must credit the Canadian Clinical Trials Group (CCTG).
SWOG Study Chair: Parminder Singh, M.D.
Patients with muscle invasive bladder cancer (MIBC) (T2-T4aN0M0).
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.